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Background:  Surgical  procedures  that  combine  both  complete  cytoreductive  surgery  (CCRS)
and hyperthermic  intraperitoneal  chemotherapy  (HIPEC)  have  improved  the  survival  of  patients
with peritoneal  carcinomatosis  (PC).  Current  imaging  and  laboratory  investigations  are  not  very
useful to  diagnose  PC.  This  prospective  study  sought  to  determine  the  usefulness  of  routine
second-look  surgery  (RSLS)  combined  with  HIPEC  in  the  diagnosis  and  treatment  of  patients
with PC  at  high-risk  for  recurrence.
Methods:  From  2007  to  2011,  RSLS  was  performed  on  14  patients  who  had  undergone  a  com-
plete initial  oncological  resection  for  synchronous  colonic  PC  and/or  ovarian  metastasis  with
PC discovered  during  primary  colon  cancer  surgery  after  a  course  of  12  cycles  of  intravenous
chemotherapy,  eventually  associated  with  HIPEC.
Results:  Pathology  conﬁrmed  PC  in  71%  of  patients  during  RSLS,  with  a  median  peritoneal  car-
cinomatosis  index  (PCI)  of  10.  There  was  no  post-operative  mortality,  while  7%  of  patients
exhibited  Dindo  Grade  III—IV  complications.  The  2-year  overall  survival  and  disease-free  sur-
vival rates  were  91%  and  38%,  respectively.  Following  RSLS  and  CCRS,  peritoneal  recurrence
was observed  in  only  8%  of  patients  who  had  undergone  HIPEC.
Conclusion:  RSLS  combined  with  HIPEC  after  initial  resection  of  synchronous  colonic  PC  allows
diagnosis and  treatment  of  low-score  PC,  with  limited  post-operative  complications  and
increased  overall  survival  rates.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.
Introduction
Median  survival  of  patients  with  peritoneal  carcinomatosis  (PC)  of  colonic  origin  has
improved  from  5.2  months  [1]  to  more  than  30  months  [2—4]  thanks  to  new  surgi-
cal  techniques  including  maximal  tumor  cytoreduction  and  hyperthermic  intraperitoneal
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hemotherapy  (HIPEC)  [5].  PC  is  the  second  most  frequent
ite  of  metastatic  recurrence  (after  the  liver)  following
esection  of  colorectal  cancer  with  curative  intent,  and
epresents  50%  of  recurrences  [6].  PC  is  present  at  initial
iagnosis  in  10  to  15%  of  patients  [7].
Pre-operative  CT  scan  before  resection  of  the  primary
olonic  tumor  does  not  always  visualize  PC  when  the  size
f  tumor  nodules  is  small  [8].  It  is  therefore  not  unusual  to
iscover  PC  during  resection  of  the  primary  cancer.
According  to  current  recommendations  [9],  in  case  of
ntra-operative  discovery  of  PC,  surgical  resection  should
ot  be  performed;  the  lesions  must  be  described  in  detail,
nd  the  patient  should  be  referred  to  a  specialized  center
or  treatment.
When  carcinomatosis  is  very  limited,  patients  can
ndergo  resection  of  visible  carcinomatosis  with  subsequent
eferral  to  the  specialized  center.  In  these  patients,  how-
ver,  PC  can  recur  early.  One  recent  study  [10]  has  shown
hat  PC  was  found  in  56%  of  completely  asymptomatic
atients  at  a  second-look  laparotomy  despite  complete
esection  followed  by  intravenous  chemotherapy.  Notwith-
tanding,  there  are  few  data  concerning  this  particular
ubgroup  of  patients.
The  goal  of  our  study  was  to  determine  the  value  of
outine  second-look  surgery  (RSLS)  after  initial  complete
ytoreductive  surgery  (CCRS)  for  synchronous  carcinomato-
is  in  a  cohort  of  patients  managed  in  our  regional  reference
enter  between  2007  and  2011.
aterial and methods
his  prospective  monocenter  study  included  all  patients
ndergoing  resection  of  PC  in  combination  with  HIPEC
etween  March  2007  and  May  2011  in  a  University  digestive
urgery  unit  in  Strasbourg,  France.
nclusion and exclusion criteria
e  included  patients:
with  synchronous  PC  and/or  ovarian  metastases  of  colonic
origin;
for  whom  carcinologic  resection  had  been  performed
(with  CCRS)  either  via  laparotomy  or  laparoscopy,  along
with  primary  tumor  excision;
followed  by  intravenous  chemotherapy;
even  if  resectable  liver  metastasis  was  present.
We  excluded  patients:
with  PC  whose  origin  was  not  colonic  (rectal,  appendiceal,
small  intestinal);
for whom  resection  of  PC  and/or  ovarian  metastases  was
not  complete;
with  metachronous  PC.
tudy design
he  initial  tumors  were  staged  according  to  TNM  classi-
cation  drawn  from  their  pathology  reports.  All  included
atients  underwent  12  cycles  of  oxaplatin  or  irinotec  or
rinotecan-based  regimen  associated  or  not  with  antiangio-
enics.  Evaluation  workup  included  thoraco-abdominopelvic
T  scan  and  carcino-embryonic  antigen  levels  dosage  (CEA)
fter  the  12  cycles  of  chemotherapy.  Pre-operative  inves-
igations  included  cerebral  CT  scan,  cardiology  workup,
aboratory  investigations,  as  well  as  anesthesia  evaluation.
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During  RSLS,  a  complete  abdominal  exploration  was  per-
ormed  via  a  routine  xyphopubic  incision.  The  extension  of
C  was  evaluated  according  to  Sugarbaker’s  Peritoneal  Car-
inomatosis  Index  (PCI)  [11]  and  Gilly’s  score  [12].  Complete
umor  cytoreduction  combined  with  HIPEC  was  performed
n  all  patients  with  macroscopic  PC  and/or  ovarian  metas-
asis  proven  by  frozen  section  biopsy,  as  long  as  the  PCI
id  not  exceed  20/39  [13].  When  PC  was  not  histologically-
onﬁrmed,  HIPEC  was  performed  in  all  patients  who  had
sked  for  it  during  pre-operative  consultation.  HIPEC  was  not
erformed  outside  these  indications.  When  resectable  liver
etastases  were  found,  treatment  included  radiofrequency
blation  or  resection.
All  intra-operatively  retrieved  tissues  were  sent  to
athology.
After  tumor  cytoreduction,  a  closed  abdomen  HIPEC
with  mitomycin  C  or  oxaliplatin,  starting  in  2009  [13])
as  performed.  Mitomycin  C  HIPEC  used  a  hyperthermic
42 ◦C)  immersion  of  mitomycin  C  (0.8  mg/kg)  in  a  periton-
al  dialysis  solution  for  90  min.  Oxaliplatin  HIPEC  included
ntravenous  calcium  folinate  (20  mg/m2)  and  5-ﬂuorouracil
400  mg/m2).  Peritoneal  immersion  with  oxaliplatin  was
osed  at  360  mg/m2 diluted  in  a  5%  glucose  solution  heated
o  42 ◦C  for  30  min.
Post-operative  morbidity  was  evaluated  according  to  the
indo-Clavien  classiﬁcation  [14].
lassiﬁcation of patients
atients  were  classiﬁed  into  three  groups  (Fig.  1):  those
ho  had  conﬁrmed  PC  and  who  were  treated  with  tumor
ytoreduction  and  HIPEC  (‘‘cytoreduction  +  HIPEC’’  group);
hose  who  had  HIPEC  without  histologic  conﬁrmation  of  PC
‘‘prophylactic  HIPEC’’  group)  and  the  one  who  did  not  have
onﬁrmed  PC  and  did  not  accept  prophylactic  HIPEC  (‘‘no
IPEC’’  group).
atient follow-up
atients  underwent  clinical  examination  at  one  month,  post-
perative  and  then  carcinologic  follow-up  was  performed
very  three  months  during  two  years  by  clinical  examination
nd  imaging.  CEA  was  measured  every  three  months.
tatistical analysis
re-operative  predictive  factors  for  severity  of  peritoneal
nvolvement  were  sought  and  analyzed  with  the  non-
arametric  Mann-Whitney  test  for  continuous  data  and
ruskal-Wallis  for  nominal  data.
A  Cox  model  was  used  to  study  the  effects  of  different
arameters  on  recurrence-free  survival.  An  adjusted  Chi2
est  was  used  to  study  dichotomic  data.  Survival  curves  were
nalyzed  according  to  Kaplan-Meier.
esults
etween  2007  and  2011,  among  115  patients  undergoing
peration  for  PC  in  our  unit,  14  met  the  inclusion  criteria  for
his  study.  Patient  characteristics  are  summarized  in  Table  1.
ean  age  at  the  time  of  RSLS  was  53.6  years  [range  28—73].
our  patients  (28.6%)  had  resectable  liver  metastases  with
o  pre-operative  imaging  evidence  of  carcinomatosis.
itoneRoutine  second-look  after  surgical  treatment  of  colonic  perFigure 1. Algorithm for intra-operative management.
The  mean  interval  between  initial  and  second-look  sur-
geries  was  10.36  months  [range  7—21].  The  mean  interval
between  the  end  of  chemotherapy  and  second-look  surgery
was  2.29  months  [range  1—4].
Four  patients  (28.6%)  had  ovarian  metastases  that  were
completely  resected  during  initial  surgery.
Presence of PC during RSLS
Twelve  patients  had  macroscopic  lesions  of  PC  found  during
RSLS  (85.7%).  After  deﬁnitive  histology,  peritoneal  metasta-
sis  was  conﬁrmed  in  10  patients  (71.4%).
Three  patients  who  did  not  have  histologically-conﬁrmed
PC  underwent  prophylactic  HIPEC  while  one  patient  did  not
have  HIPEC.
Three  patients  (21.4%)  had  suspected  PC  on  CT  scan  but
this  was  conﬁrmed  histologically  in  only  two  (14%).
Pre-chemotherapeutic  CEA  (P  =  0.439),  CEA  before  RSLS
(P  =  0.0941),  pre-operative  CT  ﬁndings  (P  =  0.837)  and  lymph
node  status  at  the  primary  tumor  site  (P  =  0.21)  were  not
statistically  signiﬁcantly  associated  with  the  presence  of  PC.
Table  1  Patient  charactereristics.
n  %
Gender
Men  6  42.9
Women  8  57.1
Primary  colonic  site
Right  5  35.7
Left—sigmoid 9  64.3
Primary  tumor  stage
T3  2  14.3
T4  12  85.7
N0  3  21.4
N1  4  286
N2  7  50
Mucinous  adenocarcinoma 6  42.9
Pre-operative  chemotherapy
FOLFOX  8  57.1
FOLFIRI  4  28.6
FOLFOX  and  FOLFIRI  2  14.3
Anti-angiogenic  drugs  9  64.3
FOLFOX: folinic acid (leucovorin) + ﬂuorouracil + oxaliplatin;
FOLFIRI: folinic acid (leucovorin) + ﬂuorouracil + irinotecan.al  carcinomatosis  151The  characteristics  and  modalities  of  surgery  as  well  as
the  post-operative  courses  are  summarized  in  Table  2.
Post-operative complications
One  patient  only  had  a  grade  III  complication  (7%),  an  infec-
tion  of  his  port-a-cath  reservoir  requiring  removal.  Thirteen
patients  had  hematologic  complications,  such  as  pancytope-
nia  or  leukopenia  (grade  II).
Follow-up, recurrence and survival
The  median  follow-up  after  RSLS  was  14  months  (mean
16.5  ±  2.8  months  [range  4—41]).  No  patient  was  lost  to
follow-up.
Overall  and  recurrence-free  survival  curves  are  found  in
Fig.  2.  At  two  years,  overall  and  recurrence-free  survival
were  91%  and  38%,  respectively.  Median  overall  survival  was
36  months.  Median  recurrence-free  survival  was  15  months.
Figure 2. Overall (blue) and recurrence-free survival (black)
according to Kaplan-Meier.
152  J.B.  Delhorme  et  al.
mes
PEC  
intrap
 and 
i
t
a
P
R
t
n
(
T
D
R
r
a
o
(
t
w
s
d
t
1
tTable  2  Characteristics  of  RSLS  and  post-operative  outco
Cytoreduction  +  HI
Number  of  patients  10  
PCI  10  [1—19]  
Gilly  score  3  [1—4]  
Number  of  resected  organs  2  [1—7]  
Duration  of  hosptial  stay  (days)  16  [11—25]  
Liver  surgery  3  
Number  of  intestinal  anastomoses  3  
Type  of  HIPEC
MMC  8  
Oxaliplatin  2  
Complications-Dindo
I—II  10  
≥  III  0  
MMC: mitomycin C; PCI: peritoneal carcinomatosis index; HIPEC: 
Median values for PCI, Gilly score, the number of resected organs
None  of  the  prognostic  factors  evaluated  had  a  signif-
cant  relationship  with  overall  recurrence,  irrespective  of
he  site  (PCI,  P  =  0.139;  Gilly  score,  P  =  0.759;  chemother-
py  protocol  used,  P  =  0.919;  use  of  anti-angiogenic  drugs,
 =  0.688;  type  of  drug  used  for  HIPEC,  P  =  0.844;  CEA  before
SLS,  P  =  0.916;  lymph  node  (N)  status,  P  =  0.71).  Conversely,
he  relationship  between  peritoneal  recurrence  and  muci-
ous  adenocarcinoma  approached  statistical  signiﬁcance
P  =  0.07).  Data  concerning  recurrence  are  summarized  in
able  3.
iscussion
outine  second-look  laparotomy  after  complete  surgical
esection  of  PC  of  colonic  origin  followed  by  intravenous
djuvant  chemotherapy  led  to  the  discovery  of  PC  in  71%
f  our  patients.  This  is  better  than  results  in  the  literature
55  and  56%  [10,15]).  A  recent  study  based  on  data  before
he  era  of  HIPEC  showed  that  peritoneal  recurrence  was  45%
hen  resection  was  not  associated  with  HIPEC  [16].
RSLS  allows  diagnosis  of  minimally  extended  PC.  In  our
tudy,  the  median  PCI  was  10,  close  to  that  of  other  known
ata  (PCI  =  10.2)  [10]  when  such  surgery  was  compared  to
hat  of  symptomatic  PC  of  colonic  origin  which  was  between
4  and  24  [17],  offering  the  possibility  of  early  curative
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Table  3  Outcomes.
Cytoreduction  +  HIPEC  
Number  of  patients  10  
Outcome
Recurrence  6  
Recurrence  site
Peritoneal  recurrence  1  
Other  metastases  5  
Death  2  
HIPEC: intraperitoneal hyperthermic chemotherapy..
Prophylactic  HIPEC  No  HIPEC  Total
3  1  14
0  0  5  [0—19]
0  0  3  [0—4]
1  [0—3]  0  2  [0—7]
20  [18—20]  16  17  [11—25]
1  0  4  (28.6%)
0  0  3  (21.4%)
3  0  11  (78.6%)
0  0  2  (14.3%)
2  1  13  (93%)
1  0  1  (7%)
eritoneal hyperthermic chemotherapy.
duration of hospital stay.
reatment.  Overall  survival  being  directly  related  to  the  PCI
18],  it  is  important  to  diagnose  PC  at  an  early  stage.
Diagnostic  performance  of  commonly  used  imaging  and
aboratory  tests  is  low  with  regard  to  detection  of  PC.  The
ensitivity  of  CT  scan  ranges  from  25.4%  to  79%  [8,19].
ikewise,  PET-CT  does  not  perform  well  for  the  diagno-
is  of  PC  [20]. In  our  study,  the  sensitivity  and  speciﬁcity
f  CT  scan  was  20%  and  75%,  respectively.  More  recently,
he  development  of  new  imaging  techniques,  in  particular
iffusion-weighted  and  3  T  MRI,  could  be  more  reliable  in
he  determination  of  PCI  [21,22].
The  diagnostic  value  of  CEA  is  also  limited;  the  CEA  level
as  2  or  less  in  more  than  50%  of  patients  with  PC  found  at
SLS.
These  diagnostic  investigations  while  certainly  minimally
nvasive,  are  not  sufﬁciently  predictive  and  should  not  pre-
lude  second-look  surgery  that  can  lead  to  early  diagnosis
f  PC  with  a  low  PCI  score  and  be  amenable  to  curative
reatment.
The  high  number  of  patients  with  recurrent
istologically-conﬁrmed  carcinomatosis  seems  to  indi-
ate  that  initially  complete  resections  by  surgeons  who  are
ot  specialists  in  the  management  of  PC  are  suboptimal
or  the  curative  management  of  PC.  It  therefore  seems
mportant  to  refer  patients  with  PC  to  specialized  centers
s  soon  as  the  diagnosis  of  PC  is  made.
Prophylactic  HIPEC  No  HIPEC  Total
3  1  14
1  1  8  (57.1%)
0  1  2  (14.3%)
1  0  6  (42.8%)
1  0  3  (21.4%)
itoneRoutine  second-look  after  surgical  treatment  of  colonic  per
Effectively,  median  survival  of  patients  undergoing
chemotherapy  alone  or  with  palliative  surgery  is  inferior
to  that  of  patients  treated  with  cytoreduction  associated
with  HIPEC:  12.6  months  vs.  22.3  months  in  the  prospective
randomized  study  of  Verwaal  [23].  Complete  tumor  cytore-
duction  alone  leads  to  median  survival  of  only  15  months
[24].  The  median  overall  survival  in  our  study  was  36  months.
The  quality  of  the  resection  is  equally  important  [23]
since  median  survival  drops  to  8—9.6  months  in  case  of
incomplete  resection  when  macroscopic  nodules  are  left
behind  [16,24].  Once  again,  this  underscores  the  need  to
perform  resective  surgery  in  centers  specialized  in  this  type
of  surgery.
Patients  in  our  series  underwent  operation  an  average
of  10.36  months  after  the  index  operation  and  2.29  months
after  the  end  of  chemotherapy.  These  data  showed  that,  in
spite  of  intravenous  chemotherapy,  PC  can  develop  rapidly,
attesting  to  insufﬁcient  peritoneal  diffusion  of  intravenously
administered  cytotoxic  drugs.
Moreover,  ‘‘prophylactic  HIPEC’’  can  be  performed  even
in  the  absence  of  biopsy  conﬁrmed  PC  and  could  lead  to
increased  survival  [10,15].
Patients  at  high  risk  of  recurrence  also  include  those
undergoing  emergency  operations  for  bleeding  or  colonic
obstruction  [25,26]  and  those  in  whom  the  tumor  is  per-
forated  during  the  initial  operation.
Effectively,  PC  has  been  observed  in  33%  of  patients  with
initially  perforated  tumors  [10].  These  patients  are  usually
not  referred  to  specialized  centers  and  none  of  our  patients
ﬁt  this  description.  It  is  important  to  recognize  patients  at
risk  to  develop  PC  for  whom  RSLS  with  HIPEC  could  be  of
beneﬁt  in  terms  of  survival  and  to  refer  these  patients  to
expert  centers  for  management.
The  small  number  of  patients  in  our  study  prevented
determination  of  any  prognostic  factors  for  the  onset  of  PC
or  the  severity  of  PC  after  initial  resection  (CEA,  CT  scan
data,  type  of  adjuvant  chemotherapy,  initial  lymph  node
status).
Literature  reports  2-year  overall  survival  of  52%  for
patients  undergoing  resection  of  PC  without  HIPEC  [16]  or
RSLS.  Overall  and  recurrence-free  survival  rates  were  91%
and  48%,  respectively,  in  our  study.  These  results  are  sim-
ilar  to  those  published  recently  by  Elias  et  al.  [15]  for
patients  undergoing  RSLS  after  initial  surgery  with  complete
resection  followed  by  intravenous  chemotherapy.
Likewise,  the  small  number  of  patients  in  our  study
prevented  demonstration  of  any  prognostic  factors  for  recur-
rence  after  RSLS.  The  only  risk  factor  for  PC  recurrence  that
approached  statistical  signiﬁcance  was  mucinous  adenocar-
cinoma.  Nearly  half  of  the  patients  in  this  study  were  in  this
case.  This  variety  of  cancer  is  associated  with  an  increased
risk  of  peritoneal  dissemination  [27]  but  PC  was  only  found
in  1.6  to  25.4%  of  colorectal  cancers  overall  [28].  A  recent
meta-analysis  [28]  has  suggested  that  mucinous  adenocarci-
noma  decreases  survival  by  2  to  8%,  even  if  the  proportion
of  stage  IV  is  not  increased.  These  data,  combined  with
ours,  suggest  that  this  type  of  tumor  is  more  resistant  to
chemotherapy  than  other  types  of  adenocarcinoma.
Overall,  57.1%  of  patients  had  recurrence.  However,  iso-
lated  peritoneal  recurrence  occurred  in  only  14.3%  of  cases
and  only  one  patient  in  the  ‘‘Cytoreduction  +  HIPEC’’  group
had  peritoneal  recurrence.  None  of  the  patients  undergo-
ing  ‘‘prophylactic  HIPEC’’  had  peritoneal  recurrence.  This  is
similar  to  the  ﬁndings  of  Elias  et  al.  published  in  2008  [10].
Conversely,  the  only  patient  who  did  not  have  ‘‘prophylactic
HIPEC’’  during  RSLS  developed  peritoneal  recurrence.  In  theal  carcinomatosis  153
literature,  the  peritoneal  recurrence  rate  is  43%  [10].  These
results  suggest  a  beneﬁcial  impact  of  prophylactic  HIPEC  in
terms  of  recurrence-free  survival.
Moreover,  as  only  10%  of  our  patients  in  the
‘‘cytoreduction  +  HIPEC’’  group  had  peritoneal  recurrence,
we  think  that  RSLS  associated  with  HIPEC  may  greatly
improved  the  peritoneal  outcome.  Elias  et  al.  [10]  reported
a  25%  recurrence  rate  in  this  same  group  of  patients.
Compared  with  a  peritoneal  recurrence  rate  of  45%  [16]
in  patients  undergoing  R0/R1  resection  of  PC  without  HIPEC,
our  results  and  those  in  the  literature  are  interesting  in
terms  of  recurrence.
Concerning  post-operative  complications,  only  one
patient  had  a  grade  III  complication.  No  patient  died  post-
operatively  in  this  series.  These  data  are  similar  to  others,
both  nationally  and  internationally  [18,29].
It  has  been  shown  that  post-operative  morbidity  was
related  to  stage  of  disease,  duration  of  operation,  the
number  of  anastomoses  and  blood  loss  [30].  It  might  also
be  related  to  the  type  of  chemotherapy  used.  The  extent
of  surgery  performed  therefore  seems  to  be  an  important
factor  for  post-operative  complications.  We  did  not  ﬁnd
any  difference  between  the  ‘‘cytoreduction  +  HIPEC’’  group
whose  mean  PCI  was  10,  and  the  ‘‘prophylactic  HIPEC’’
group  as  concerned  the  occurrence  of  post-operative
complications:  the  earlier  the  treatment,  the  less  severe
the  complications.  This  is  similar  to  the  median  hospital  stay
between  the  two  groups  of  patients.  These  results  suggest
that  post-operative  complications  are  due  not  only  to  com-
plete  cytoreduction  but  also  to  the  toxicity  of  HIPEC  in  itself,
essentially  with  hematological  consequences.
The  potential  beneﬁts  in  terms  of  overall  and  recurrence-
free  survival  reported  after  RSLS  in  high-risk  patients  seems
to  be  in  favor  of  this  therapeutic  option,  in  spite  of
the  potential  post-operative  complications  in  asymptomatic
patients.
Conclusion
Routine  second-look  laparotomy  with  HIPEC  after  initial
complete  resection  of  synchronous  PC  originating  from
colonic  cancer  leads  to  the  diagnosis  of  limited  periton-
eal  recurrence  in  71%  of  patients.  This  therapeutic  modality
is  associated  with  low  morbidity  and  high  survival  rates.  It
seems  important  to  offer  this  option  to  high-risk  patients  in
referral  centers.  The  outcomes  observed  in  this  small  cohort
of  patients  should  be  conﬁrmed  by  controlled  randomized
studies.  In  France,  a  phase  III  multicentric  study  (PROPHY-
LOCHIP)  is  underway,  comparing  simple  surveillance  versus
exploratory  laparotomy  combined  with  HIPEC  in  patients
with  synchronous  colorectal  peritoneal  metastases  treated
initially  by  surgery  and  adjuvant  chemotherapy  and  at  high
risk  to  develop  peritoneal  carcinomatosis.
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